Equecabtagene Autoleucel is named as a drug or biological intervention in 4 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Nanjing IASO Biotechnology Co., Ltd. (2), Peking University People's Hospital (1) and Tongji Hospital (1). Registered phases: Phase 3, Observational, Not applicable and Phase 1/2. Conditions studied include Multiple Myeloma; Relapsed/Refractory Multiple Myeloma; Systemic Lupus Erythematosus (SLE).
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06464991 | A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) (ClinicalTrials.gov ↗) Multiple Myeloma |
Phase 3 | Recruiting |
| NCT06902844 | Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE) (ClinicalTrials.gov ↗) Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) |
Not applicable | Recruiting |
| NCT07752264 | A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy (ClinicalTrials.gov ↗) Refractory Immune-mediated Necrotizing Myopathy |
Phase 1/2 | Not yet open |
| NCT06369935 | A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. (ClinicalTrials.gov ↗) Relapsed/Refractory Multiple Myeloma |
Observational | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Multiple Myeloma | 1 |
| Relapsed/Refractory Multiple Myeloma | 1 |
| Systemic Lupus Erythematosus (SLE) | 1 |
| Lupus Nephritis (LN) | 1 |
| Refractory Immune-mediated Necrotizing Myopathy | 1 |
| Lead sponsor | Trials |
|---|---|
| Nanjing IASO Biotechnology Co., Ltd. | 2 |
| Peking University People's Hospital | 1 |
| Tongji Hospital | 1 |
| Register | Equecabtagene Autoleucel trials |
|---|---|
| Clinical trials in China | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Equecabtagene Autoleucel works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Equecabtagene Autoleucel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.